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Kris Nackaerts, MD, PhD, and Johan Vansteenkiste, MD, PhD
After the disappointing experience with lung cancer screening studies based on chestx-ray and/or sputum cytology several decades ago, great expectations are now in place
on screening with modern low-dose spiral computed tomography (LDSCT) scan. The
prevalence data of one of these randomized studies is reported in this issue of our journal.1
The definition of screening—adapted from Stedman’s Concise dictionary—consists
of an examination of a group of usually asymptomatic individuals to detect those with a
high probability of having a given disease, typically by means of an inexpensive, safe, and
well-performing diagnostic test.2 To reach the real goal—reduction of lung cancer related
mortality—four conditions need to be in place: a sensitive test for detection of small
lesions; small lesions need to be associated with truly early stage disease; an effective
treatment is available for these lesions; and acceptable morbidity and cost of the screening tool.
Screening for lung cancer by LDSCT has been studied extensively in the past
decade, and it looks like this might become the long awaited tool. Looks like, because
until today, all the available data have been gathered from many—some even very
large—cohort studies, but not yet from large randomized controlled trials. These nonran-
domized studies show promising results. In the I-ELCAP trial in asymptomatic smokers
or past smokers, for instance, 85% of lung cancers were detected in stage I, and the
estimated 10-year survival rate of patients whose stage I lung cancer was removed by
surgery was 92%.3 This suggests that LDSCT is a sensitive tool that is able to detect small
lesions associated with truly early stage, for which an effective therapy is available. This
does not prove, however, that the strategy results in a reduction of lung cancer related
mortality. This evidence can only come from the eagerly awaited results from two large
randomized controlled trials that are currently running, the American National Lung
Screening Trial, started in 2002, and the Dutch-Belgian Nederlands-Leuvens Longkanker
Screening Onderzoek (NELSON) trial, started in 2003.4,5 The long-term postscreening
follow-up on the primary end point of reduction of lung cancer mortality in participants
in the National Lung Screening Trial and the NELSON trial is planned to end in 2009 and
2014, respectively. Until then, the “pro and con debate” on CT screening for lung cancer
will probably remain a “battle over lung scans.”6,7
Some other, smaller RCTs have been setup in Italy, France, and in Denmark, the
Danish randomized lung cancer CT screening trial (DLCST), whose first round or
prevalence CT results are reported now.1 This DLCST has been designed in accordance
with the NELSON trial to allow pooling of both study data together once both screening
trials will have been finished. The combined data on lung cancer-specific mortality of
around 20,000 included individuals will then give these two CT lung cancer screening
trials an 80% power to show a lung cancer mortality reduction of at least 25%.5
Although waiting for the final results of these trials’ follow-up period by the year
2014, it is interesting to compare the first round CT screening results of the DLCST to the
previously reported results from other series. The lung cancer detection rate of 0.83% (17
cases of lung cancer in 2052 participants) is lower than previously reported in nonran-
domized CT screening trials. As pointed out by the authors, this result is not easily
explainable at this time, and results of the lung cancer prevalence in their control group
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also need to be awaited. What is probably more important is
the stage distribution of lung cancers that were detected in the
randomized Danish trial: only 53% of screen detected lung
cancers were stage I, definitely lower than in the International
Early Lung Cancer Action Program trial. Around 65% of all
screen-detected lung cancers in the DLCST could be surgi-
cally resected. How this all will translate into better progno-
sis, improved lung cancer survival and, most importantly,
lower lung cancer mortality figures for the screening partic-
ipants is very difficult to predict at present.
Even if lung cancer screening with LDSCT would
become a validated screening method, its applicability in
large parts of the world will be debated, for its safety and
cost-effectiveness. One issue will be the most appropriate
algorithm to be used for further diagnosis of noncalcified
nodules that will often be detected on LDSCT, to reduce the
number of invasive tests for benign nodules, and whether this
algorithm can be improved by, e.g., use of more precise
estimations of growth by computer-aided volumetric mea-
surements, or by selective use of 18Fluorodeoxyglucose-
positron emission tomography scan.8 Another question will
be the exact definition of a high-risk population to target for
lung cancer screening. Lung cancer risk models (such as the
Liverpool Lung Project model) combining different epidemi-
ological risk factors besides smoking history have been de-
veloped and will also need to be further validated.9
Until that time, we strongly endorse different interna-
tional medical society guidelines that screening for lung
cancer in asymptomatic individuals with LDSCT is not ready
for widespread clinical practice in 2009.10,11 Recently re-
ported efforts of total body screening of healthy individuals
with CT scan, magnetic resonance imaging, or even FDG-
positron emission tomography scan12 similarly belong in
clinical trial settings at present. It would be an error to
promote LDSCT screening for lung cancer as an evidence-
based screening method at present, but we all have hopes
that—in a few years’ time—we do not need to conclude that
this whole idea of trials was an error. Lung cancer continues
to be the leading cause of cancer deaths, and a successful
strategy to reduce lung cancer mortality is desperately needed.
Although awaiting the final results of the randomized
trials, it would certainly be an error not to address the main
cause of lung cancer, tobacco smoking. What we know for
sure at present is that ignoring or not sufficiently addressing
the need for smoking cessation of patients in our lung cancer
screening trials and in our daily clinical practice, really would
be the unforgivable error. We should avoid it, by using
counseling and smoking cessation aids whenever possible.
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